CervoMed to present at H.C. Wainwright and Morgan Stanley conferences in September.

CervoMed Inc., a clinical-stage company focused on age-related neurologic disorders, announced management participation in investor conferences during September. The events include H.C. Wainwright's 27th Annual Global Investment Conference and Morgan Stanley's 23rd Annual Global Healthcare Conference. A fireside chat webcast will be available on the CervoMed website. The company is developing neflamapimod, an investigational treatment for age-related neurologic disorders.

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company specializing in treatments for age-related neurologic disorders, has announced its participation in two significant investor conferences in September 2025. The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, from 2:00 to 2:30 PM ET, with both a presentation and one-on-one investor meetings [1]. Additionally, CervoMed will participate in Morgan Stanley's 23rd Annual Global Healthcare Conference from September 8-10, 2025, featuring one-on-one investor meetings [1].

The H.C. Wainwright 27th Annual Global Investment Conference will take place in Boston, MA, and the webcast of the presentation will be accessible at the link provided [1]. The Morgan Stanley conference will also be held in Boston, with the webcast of the fireside chat available in the Investor section of the CervoMed website [1].

CervoMed is currently developing neflamapimod, an investigational, orally administered small molecule that inhibits p38 mitogen-activated protein kinase alpha. This drug has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB [1].

The company has recently reported positive data from the 32-week Extension phase of the Phase 2b RewinD-LB trial for neflamapimod in DLB, showing a 54% risk reduction in clinically significant worsening compared to control, improving to 64% in patients with minimal Alzheimer's Disease co-pathology [2]. The company plans to meet with the FDA in Q4 2025 to discuss Phase 3 trial design for this potential treatment of the second most common form of dementia.

CervoMed's participation in these investor conferences provides an opportunity for stakeholders to gain insights into the company's progress and plans for the future. The company's management will engage with investors to discuss the latest developments in their drug pipeline, including the Phase 2b trial for neflamapimod and the potential for Phase 3 trials in the future.

References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143494/0/en/CervoMed-to-Participate-in-Upcoming-Investor-Conferences.html
[2] https://www.stocktitan.net/news/CRVO/